Automate Your Wheel Strategy on MLTX
With Tiblio's Option Bot, you can configure your own wheel strategy including MLTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MLTX
- Rev/Share 0.0016
- Book/Share 5.6563
- PB 1.5493
- Debt/Equity 0.2142
- CurrentRatio 16.6471
- ROIC -0.4611
- MktCap 549922124.0
- FreeCF/Share -2.6352
- PFCF -3.2977
- PE -3.1055
- Debt/Assets 0.1647
- DivYield 0
- ROE -0.4161
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MLTX | H.C. Wainwright | Buy | Neutral | -- | -- | Oct. 2, 2025 |
| Downgrade | MLTX | Goldman | Buy | Neutral | -- | $7 | Oct. 1, 2025 |
| Downgrade | MLTX | Citigroup | Buy | Neutral | -- | $5 | Sept. 30, 2025 |
| Downgrade | MLTX | Wolfe Research | Outperform | Underperform | -- | $2 | Sept. 30, 2025 |
| Downgrade | MLTX | BTIG Research | Buy | Neutral | -- | -- | Sept. 29, 2025 |
| Downgrade | MLTX | Jefferies | Buy | Hold | -- | $8 | Sept. 29, 2025 |
| Downgrade | MLTX | RBC Capital Mkts | Outperform | Sector Perform | -- | $10 | Sept. 29, 2025 |
| Downgrade | MLTX | Stifel | Buy | Hold | -- | $13 | Sept. 29, 2025 |
| Initiation | MLTX | Rothschild & Co Redburn | -- | Neutral | -- | $65 | July 28, 2025 |
| Upgrade | MLTX | Wolfe Research | Peer Perform | Outperform | -- | $61 | May 19, 2025 |
News
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm
Published: October 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Moon Lake and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Read More
MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm's Investigation
Published: October 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations. Investors who have lost money in their MoonLake Immunotherapeutics investment should contact the firm to learn more about how they might recover those losses.
Read More
MLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public.
Read More
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) saw the price of their shares crater $55.75, or about 90%, after the company announced disastrous VELA-2 trial results for sonelokimab, its highly anticipated treatment for patients with skin disease (hidradenitis suppurative or “HS”). The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether MoonLake may have misled investors about sonelokimab's trial design and efficacy.
Read More
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options If you suffered significant losses in MoonLake stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTX
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("Moonlake" or the "Company") (NASDAQ: MLTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
Published: October 01, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX.
Read More
MoonLake Investor News: Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MLTX
Published: October 01, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public. So What: If you purchased MoonLake securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar.
Read More
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
Published: October 01, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $MLTX--MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm.
Read More
MLTX INVESTIGATION ALERT: MoonLake Immunotherapeutics Trial Results Triggers Securities Fraud Investigation after Stock Plummets 90% -- Investors Urged to Contact BFA Law
Published: September 30, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $MLTX #BFALaw--MoonLake Immunotherapeutics investors that lost money are notified to contact BFA Law about its ongoing securities fraud class action investigation.
Read More
INVESTOR ALERT: Investigation of MoonLake Immunotherapeutics (MLTX) Announced by Holzer & Holzer, LLC
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQE: MLTX) complied with federal securities laws. On September 28, 2025, MoonLake reported results from its VELA-1 and VELA-2 Phase 3 program, disclosing that in “VELA-2, intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy.” Following this news, the price of the Company's stock dropped.
Read More
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
Read More
MoonLake Immunotherapeutics analysts slash target price as trial results disappoint
Published: September 29, 2025 by: Proactive Investors
Sentiment: Negative
RBC analysts cut their target price on MoonLake Immunotherapeutics (NASDAQ: MLTX) to $10 per share, from $67 previously, after the biotechnology company reported trial results for its highly anticipated skin disease treatment, sonelokimab, which they called “disappointing”. The analysts also downgraded the stock to ‘Sector Perform' from ‘Outperform', citing meaningfully lower market opportunity, pending further clarity.
Read More
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Published: September 29, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $MLTX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. MoonLake Immunotherapeutics saw its shares p.
Read More
BREAKING: MoonLake Immunotherapeutics Shares Down Over 85%; Investors Should Contact Block & Leviton to Potentially Recover Losses
Published: September 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations.
Read More
Moonlake: What's Happening With MLTX Stock?
Published: September 29, 2025 by: Forbes
Sentiment: Positive
MoonLake Immunotherapeutics (NASDAQ: MLTX), a biopharmaceutical firm in the clinical stage, experienced substantial fluctuations last week. The stock climbed 10% on Friday, September 26, as investors expected favorable outcomes from Phase 3 trials of sonelokimab for hidradenitis suppurativa.
Read More
2 Logical Mid-Cap Biotech Buyout Targets
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on their own, but would make logical buyout candidates: Abivax Société Anonyme and MoonLake Immunotherapeutics. Both have late-stage assets targeting large markets, and both companies should file for their first FDA approvals in 2026.
Read More
2 Small-Cap Biotech Stocks Well Positioned for a Breakout
Published: August 27, 2025 by: The Motley Fool
Sentiment: Positive
For decades, savvy investors have been finding stocks that can produce dramatic gains in relatively short timeframes by sifting through the biotechnology universe. In this wonky industry, positive clinical trial results can cause small-cap stocks to double in value in a single trading session.
Read More
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.
Read More
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Positive
MoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is projected to reach $24.2 billion by the end of 2031. Merck's $3 billion non-binding acquisition offer highlights significant buyout potential of company and validates its late-stage pipeline value.
Read More
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake's strategy and funding needs.
Read More
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced its financial results for the fourth quarter and year ended December 31, 2024.
Read More
About MoonLake Immunotherapeutics (MLTX)
- IPO Date 2020-10-20
- Website https://www.moonlaketx.com
- Industry Biotechnology
- CEO Jorge Santos da Silva
- Employees 100